AU2021355240B2 - Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium - Google Patents

Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium

Info

Publication number
AU2021355240B2
AU2021355240B2 AU2021355240A AU2021355240A AU2021355240B2 AU 2021355240 B2 AU2021355240 B2 AU 2021355240B2 AU 2021355240 A AU2021355240 A AU 2021355240A AU 2021355240 A AU2021355240 A AU 2021355240A AU 2021355240 B2 AU2021355240 B2 AU 2021355240B2
Authority
AU
Australia
Prior art keywords
bacteria
ruminococcaceae
enterobacterium
cancer
firmicutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021355240A
Other languages
English (en)
Other versions
AU2021355240A1 (en
AU2021355240A9 (en
Inventor
Yoshimi Benno
Shota FUKUOKA
Hiroyoshi Nishikawa
Yuko SHIGENO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
National Cancer Center Korea
Original Assignee
National Cancer Center Japan
RIKEN
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, RIKEN, National Cancer Center Korea filed Critical National Cancer Center Japan
Publication of AU2021355240A1 publication Critical patent/AU2021355240A1/en
Publication of AU2021355240A9 publication Critical patent/AU2021355240A9/en
Application granted granted Critical
Publication of AU2021355240B2 publication Critical patent/AU2021355240B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2021355240A 2020-09-30 2021-09-29 Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium Active AU2021355240B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-165470 2020-09-30
JP2020165470 2020-09-30
PCT/JP2021/035941 WO2022071423A1 (ja) 2020-09-30 2021-09-29 ルミノコッカッセ腸内菌投与による免疫チェックポイント阻害薬の抗腫瘍効果の増強

Publications (3)

Publication Number Publication Date
AU2021355240A1 AU2021355240A1 (en) 2023-05-25
AU2021355240A9 AU2021355240A9 (en) 2024-09-26
AU2021355240B2 true AU2021355240B2 (en) 2026-04-16

Family

ID=80950658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021355240A Active AU2021355240B2 (en) 2020-09-30 2021-09-29 Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium

Country Status (8)

Country Link
US (1) US20230364163A1 (https=)
EP (1) EP4223868A4 (https=)
JP (1) JP7852863B2 (https=)
CN (1) CN116322721A (https=)
AU (1) AU2021355240B2 (https=)
CA (1) CA3202362A1 (https=)
TW (1) TW202227611A (https=)
WO (1) WO2022071423A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312781A (en) * 2021-11-11 2024-07-01 Microba Ip Pty Ltd Compositions and methods for treating disease
CN116103196B (zh) * 2022-12-14 2023-10-20 中国科学院微生物研究所 一种活泼瘤胃球菌及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
WO2018226690A1 (en) * 2017-06-05 2018-12-13 The University Of Chicago Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
WO2019032572A1 (en) * 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES
WO2019169160A1 (en) * 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using ruminococcus gnavus
WO2019191390A2 (en) * 2018-03-28 2019-10-03 Seres Therapeutics, Inc. Treatment of a cancer by microbiome modulation
JP2020500151A (ja) * 2016-09-27 2020-01-09 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
JP2020512294A (ja) * 2016-12-22 2020-04-23 アンスティテュ ギュスタブ ルシ 抗ｐｄ１／ｐｄ−ｌ１／ｐｄ−ｌ２抗体に対する反応性のマーカーとしての微生物叢組成物と、抗ｐｄ１／ｐｄ−ｌ１／ｐｄ−ｌ２抗体をベースとした治療剤の効果を改善させるための微生物モジュレータの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118340799A (zh) * 2020-02-27 2024-07-16 上海上药信谊药厂有限公司 抗肿瘤组合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
JP2020500151A (ja) * 2016-09-27 2020-01-09 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
JP2020512294A (ja) * 2016-12-22 2020-04-23 アンスティテュ ギュスタブ ルシ 抗ｐｄ１／ｐｄ−ｌ１／ｐｄ−ｌ２抗体に対する反応性のマーカーとしての微生物叢組成物と、抗ｐｄ１／ｐｄ−ｌ１／ｐｄ−ｌ２抗体をベースとした治療剤の効果を改善させるための微生物モジュレータの使用
WO2018226690A1 (en) * 2017-06-05 2018-12-13 The University Of Chicago Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
WO2019032572A1 (en) * 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES
WO2019169160A1 (en) * 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using ruminococcus gnavus
WO2019191390A2 (en) * 2018-03-28 2019-10-03 Seres Therapeutics, Inc. Treatment of a cancer by microbiome modulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. SPRANGER, M. JAVOROVIC, M. BURDEK, S. WILDE, B. MOSETTER, S. TIPPMER, I. BIGALKE, C. GEIGER, D. J. SCHENDEL, B. FRANKENBERGER: "Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, vol. 185, no. 1, 1 July 2010 (2010-07-01), pages 738 - 747, XP055040250, ISSN: 00221767, DOI: 10.4049/jimmunol.1000060 *

Also Published As

Publication number Publication date
EP4223868A1 (en) 2023-08-09
JPWO2022071423A1 (https=) 2022-04-07
WO2022071423A1 (ja) 2022-04-07
JP7852863B2 (ja) 2026-04-28
US20230364163A1 (en) 2023-11-16
TW202227611A (zh) 2022-07-16
EP4223868A4 (en) 2025-02-12
CN116322721A (zh) 2023-06-23
AU2021355240A1 (en) 2023-05-25
CA3202362A1 (en) 2022-04-07
AU2021355240A9 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
Li et al. Prebiotic-induced anti-tumor immunity attenuates tumor growth
Rong et al. Reactivity toward Bifidobacterium longum and Enterococcus hirae demonstrate robust CD8+ T cell response and better prognosis in HBV-related hepatocellular carcinoma
Xie et al. The role of the gut microbiota in tumor, immunity, and immunotherapy
Li et al. Ganoderma lucidum polysaccharide supplementation significantly activates T-cell-mediated antitumor immunity and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer
Wu et al. Arctigenin exerts anti-colitis efficacy through inhibiting the differentiation of Th1 and Th17 cells via an mTORC1-dependent pathway
Xia et al. PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancer
Eslami et al. Lactobacillus crispatus strain SJ‐3C‐US induces human dendritic cells (DCs) maturation and confers an anti‐inflammatory phenotype to DCs
Fallarini et al. Invariant NKT cells increase drug‐induced osteosarcoma cell death
Zhou et al. Macrophages polarization is mediated by the combination of PRR ligands and distinct inflammatory cytokines
EP3166616B1 (en) Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
Wang et al. Mushroom β‐glucan May Immunomodulate The Tumor‐associated Macrophages in The Lewis Lung Carcinoma
AU2021355240B2 (en) Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium
Ke et al. The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo
Hsu et al. Reishi Protein LZ‐8 Induces FOXP3+ Treg Expansion via a CD45‐Dependent Signaling Pathway and Alleviates Acute Intestinal Inflammation in Mice
Zhou et al. Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy
Campeau et al. Intestinal epithelial cells modulate antigen-presenting cell responses to bacterial DNA
Masad et al. Oral administration of Manuka honey induces IFNγ-dependent resistance to tumor growth that correlates with beneficial modulation of gut microbiota composition
Li et al. Nondigestible stachyose binds membranous HSP90β on small intestinal epithelium to regulate the exosomal miRNAs: A new function and mechanism
Zhang et al. Pseudomonas aeruginosa-mannose sensitive hemagglutinin injection treated cytokine-induced killer cells combined with chemotherapy in the treatment of malignancies
Li et al. Influence of gut microbial metabolites on tumor immunotherapy: Mechanisms and potential natural products
Hovden et al. The bacterial preparation OK432 induces IL-12p70 secretion in human dendritic cells in a TLR3 dependent manner
Tian et al. New mechanisms and therapeutic targets in systemic lupus erythematosus
Kunanopparat et al. Complement receptor 3-dependent engagement by Candida glabrata β-glucan modulates dendritic cells to induce regulatory T-cell expansion
Klaimi et al. The immunological interface: dendritic cells as key regulators in metabolic dysfunction‐associated steatotic liver disease
Bonomi et al. Human CD14+ cells loaded with Paclitaxel inhibit in vitro cell proliferation of glioblastoma

Legal Events

Date Code Title Description
SREP Specification republished